Our results indicate that prophylactic tocilizumab is feasible in NHL patients receiving anti-CD19 CAR-T cells with CD3ζ/4-1BB costimulatory signaling, without increased risk of ICANS and with preserved disease control. Here, CD19 is linked to non-Hodgkin lymphoma.